Quarterly report · Q2
9987.TEDINET S100S6ZT
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.19T | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥2.31T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.14T | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥16.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥14.9bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥18.2bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥36.4bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.7bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥23.0bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥16.5bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥15.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥10.8bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥15.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥10.8bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥1.32T | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥1.15T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.19T | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥889.5bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥734.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥427.9bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥411.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥429.1bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥202.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥109.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥223.9bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥132.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥155.8bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥86.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥37.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥28.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥8.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥46.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥37.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥26.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥191.98 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.56 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥236.47 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.36 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.86 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.5% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.9% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥48.6bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥48.6bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9m |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥519m |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥25.4bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥19.6bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥127.0bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥14.2bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥112.8bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥510m |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.15T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.13T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥25.4bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥14.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.35T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.19T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥157.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥16.5bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥48.4bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥48.4bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥956m |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥23.4bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥17.3bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥101.3bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥14.3bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥87.1bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥578m |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.09T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.07T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥25.1bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥12.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥1.27T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥1.14T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥129.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥14.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 492
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 3000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 87091000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 129514000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 1094771000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 23350000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 48353000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 101349000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1267825000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 12137000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 1055000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 956000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 578000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 14728000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 1125845000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 5818000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 48612000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 14196000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1194472000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 25429000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 19614000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 9000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 112849000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 157901000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 1151274000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 25432000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 48621000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 127046000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1352374000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 14061000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 1401000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 519000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 510000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 16493000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-11-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第78期 第２四半期(自 2023年７月１日 至 2023年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社スズケン | |
| Company name in english cover page | FilingDateInstant | SUZUKEN CO.,LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 浅野 茂 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)名古屋市東区東片端町８番地 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)052(961)2331（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)経営管理部長 長縄 淳 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)名古屋市東区東片端町８番地 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)052(961)2331（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)経営管理部長 長縄 淳 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E02780 | |
| Fund code | FilingDateInstant | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |